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Abstract 
Background 
Our understanding of the complex relationship between schizophrenia symptomatology and 
etiological factors can be improved by studying brain-based correlates of schizophrenia. 
Research showed that impairments in value processing and executive functioning, which 
have been associated with prefrontal brain areas (particularly the medial orbitofrontal 
cortex (MOFC)), are linked to negative symptoms. Here we tested the hypothesis that MOFC 
thickness is associated with negative symptom severity.  
Methods 
This study included 1 985 individuals with schizophrenia from seventeen research groups 
around the world contributing to the ENIGMA Schizophrenia Working Group. Cortical 
thickness values were obtained from T1-weighted structural brain scans using FreeSurfer. A 
meta-analysis across sites was conducted over effect sizes from a model predicting cortical 
thickness by negative symptom score (harmonized SANS or PANSS scores).  
Results 
Meta-analytical results showed that left, but not right, MOFC thickness was significantly 
associated with negative symptom severity (βstd=-0.075; p=0.019) after accounting for age, 
gender and site. This effect remained significant (p=0.036) in a model including overall 
illness severity. Covarying for duration of illness, age of onset, antipsychotic medication or 
Walton et al.                                                                           Negative symptoms and cortical thinning 
 
8 
 
handedness weakened the association of negative symptoms with left MOFC thickness. As 
part of a secondary analysis including ten other prefrontal regions further associations in the 
left lateral orbitofrontal gyrus and pars opercularis emerged. 
Conclusions 
Using an unusually large cohort and a meta-analytical approach, our findings point towards 
a link between prefrontal thinning and negative symptom severity in schizophrenia. This 
finding provides further insight into the relationship between structural brain abnormalities 
and negative symptoms in schizophrenia.    
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Introduction 
Although advances have been made in our understanding of the pathophysiology of 
schizophrenia, the heterogeneity of the disorder impedes the effectiveness of biological and 
clinical research. The large number of cognitive and clinical symptoms within the syndrome 
and their considerable variability across patients likely reflects the impact of various 
etiological factors (Jablensky, 2006). Such variability makes it harder to achieve a 
comprehensive understanding underlying brain pathology. Investigations using large sample 
sizes to study symptoms associated with dimensions of behavior that can be measured 
quantitatively, may advance our understanding of brain behavior relationships within as 
well as across diagnostic categories. Investigating distinct symptoms of the disorder as a 
continuous variable may reveal more specific neurobiological mechanisms in schizophrenia.  
Negative symptoms are characterized by flat or blunted affect, inability to 
experience pleasure (anhedonia), poverty of speech, lack of motivation and interest 
(avolition/apathy) and lack of desire to form relationships (Andreasen & Olsen, 1982). 
Patients with predominantly negative symptoms have poor pre-morbid adjustment during 
childhood or early adolescence and a low employment rate during adulthood, achieve low 
educational attainment and exhibit considerable cognitive impairment (Milev et al. 2005; 
Rosenheck et al. 2006; Jeppesen et al. 2008).  
Studies have shown widespread cortical thickness reductions across the brain in 
patients with schizophrenia compared to healthy controls with frontal and temporal regions 
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being generally more affected than others areas (Nesvåg et al. 2008; Goldman, 2009; 
Schultz et al. 2010). In line with prior work, Ehrlich et al. (2012) and Geisler et al. (2015) 
recently reported marked reductions of cortical thickness in patients with schizophrenia, 
which were also related to executive functioning.  
Executive functioning is often driven by incentives and motivation (Pessoa, 2009). 
When we make decisions between options with different (subjective) value or learn from 
positive or negative feedback, those processes are governed by a neural circuit that centers 
around structures such as the ventral striatum and the medial orbitofrontal cortex (MOFC) 
(Schlagenhauf et al. 2014; Deserno et al. 2016). Within this circuit, the MOFC is 
predominately linked to (subjective) value processing and positive affect (Burgdorf & 
Panksepp, 2006; Peters & Büchel, 2010; Grabenhorst & Rolls, 2011; Liu et al. 2011; Price & 
Harmon-Jones, 2011; Berridge & Kringelbach, 2015), which is impaired in schizophrenia 
(Cohen & Minor, 2010; Kalkstein et al. 2010). MOFC lesions in humans relate to deficits in 
reward-based learning, which can result in apathy and lack of affect (Hornak et al. 2003; 
Fellows & Farah, 2005; Fisher et al. 2011; Kühn & Gallinat, 2012). Accordingly, functional 
and structural imaging studies in healthy cohorts have reported associations between MOFC 
activity (and thickness) and characteristics that are comparable to the negative symptoms 
observed in schizophrenia (Harvey et al. 2007; Ducharme et al. 2014). For instance, 
functional connectivity between the orbitofrontal cortex and the dorsolateral prefrontal 
cortex was found to be dependent on levels of motivation (Szatkowska et al. 2008). 
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Given these findings one could hypothesize that altered brain structure and 
functioning in the orbitofrontal cortex may represent one of the potential mechanisms 
underlying negative symptoms in schizophrenia. This is motivated by the idea that i) neural 
representations of decision values may not be adequately generated and ii) reward 
feedback might not get completely transformed into motivational drive for goal-directed 
behaviour (Barch & Dowd, 2010; Deserno et al. 2013).  
Several functional imaging studies have assessed the brain-based correlates of 
negative symptoms in schizophrenia. An early PET study found lower perfusion of several 
brain regions – including the MOFC – during hedonic judgments of positive and negative 
visual stimuli in patients with schizophrenia  (Plailly et al. 2006). More recent fMRI studies in 
patients with schizophrenia found neural responses in the medial prefrontal cortex to be 
exaggerated upon omission of expected reward but blunted upon receipt of unexpected 
reward  (Schlagenhauf et al. 2009). Simon et al. (2015) showed that neural responses in the 
ventral striatum during a reward anticipation paradigm were negatively associated with 
apathy – a core negative symptom; while no associations between ventral striatal responses 
and positive symptoms were observed. Importantly, they found lower connectivity between 
the ventral striatum and the MOFC in individuals with schizophrenia compared with 
controls. Furthermore, in one of the aforementioned studies focussing on receipt of 
unexpected reward in schizophrenia, medial frontal cortical activation predicted task-
related motivation, which in turn predicted anhedonia severity (Segarra et al. 2016). In line 
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with this, another study could show that activity in the orbitofrontal cortex during hedonic 
processing was negatively correlated with anhedonia severity in people with schizophrenia 
(Harvey et al. 2010).  
With respect to structural imaging, gray matter density of the orbitofrontal cortex 
has also been associated with self-fulfillment achievement motivation in healthy individuals 
(Takeuchi et al. 2014). In patients with schizophrenia, Venkatasubramanian et al. (2008) 
found that lower left MOFC thickness was associated with higher negative symptom 
severity. Similar findings have been reported by Nenadic et al. (2015), providing further 
evidence for the involvement of medial prefrontal regions in negative symptoms; though 
some negative findings also exist (Crespo-Facorro et al. 2011; Xiao et al. 2013). 
Reasons for these inconsistencies may be two-fold. First, most studies conducted to 
date have had rather moderate sample sizes, investigating on average about a hundred 
patients. Second, moderating effects of confounders such as antipsychotic medication, 
illness severity, or duration of illness that may influence the association between thickness 
and negative symptoms have not been investigated extensively. Analyses of larger samples 
will increase power allowing to understand prior inconsistencies in findings as well as to 
study potential moderator effects.  
Here we set out to investigate the structural correlates of negative symptoms in a 
large meta-analysis including almost 2 000 individuals with schizophrenia. Based on previous 
structural imaging findings, we hypothesised that lower MOFC thickness is associated with 
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negative symptom severity in schizophrenia. As part of an exploratory analysis we also 
aimed to understand relationships with cortical thickness in other prefrontal brain regions. 
 
Methods 
Study samples 
The current study includes a total of 1 985 individuals with schizophrenia or 
schizophrenia spectrum diagnoses (see also SM section 2.1, subsection s) from seventeen 
research groups around the world as part of the ENIGMA Schizophrenia Working Group as 
described previously (van Erp et al. 2015). Schizophrenia diagnosis was based on the 
Diagnostic and Statistical Manual of Mental Disorders (DSM, editions III-R or IV) or the 
International Classification of Diseases (ICD, edition 10) criteria using either the Structured 
Clinical Interview for DSM Disorders (SCID), the Comprehensive Assessment of Symptoms 
and History (CASH), the Present State Examination (PSE), and/or a review of case 
files/medical records by trained clinicians. All individuals had negative symptom ratings and 
structural imaging data available. Mean sample size at each research site was 117 patients 
(range: 23-244). See supplementary Table 1s for more details. 
Each study sample was collected with participants’ written informed consent 
approved by local Institutional Review Boards. The authors assert that all procedures 
contributing to this work comply with the ethical standards of the relevant national and 
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institutional committees on human experimentation and with the Helsinki Declaration of 
1975, as revised in 2008. No individual subject imaging or clinical data were shared among 
the ENIGMA institutions. 
 
Negative symptom measures and score conversion 
Negative symptom severity was assessed using the Scale for the Assessment of Negative 
Symptoms (SANS) (Andreasen, 1983) and the Positive and Negative Syndrome Scale (PANSS) 
(Kay et al. 1987). Negative symptom scores were calculated as follows: 
1. Total SANS (Composite) score = sum of SANS items 1-7, 9-12, 14-16, 18-21, and 23-
24; 
2. Global SANS (Summary) score = sum of SANS items 8, 13, 17, 22, and 25 (which 
include affective flattening, alogia, avolition, anhedonia, and attention global rating 
scores, respectively); or 
3. PANSS Negative = sum of PANSS items 8-14. 
To harmonize scores, we decided to convert all negative scores (i.e. PANSS Negative and 
Total SANS Composite scores) to Global SANS (Summary) scores following recommendations 
by Andreasen (1983) and using the algorithms published in van Erp et al. (2014). For 
additional details see supplementary Section 1.1. 
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Image acquisition and processing 
Based on the previous literature (Venkatasubramanian et al. 2008; Nenadic et al. 
2015) we followed a region-of-interest (ROI) approach, focusing on the medial orbitofrontal 
cortex (MOFC), while ten other prefrontal regions were considered in additional exploratory 
analyses (see SM section 2.2). Left and right MOFC thickness values – based on the Desikan-
Killiany atlas (Desikan et al. 2006) - were obtained using FreeSurfer 
(http://surfer.nmr.mgh.harvard.edu) from high-resolution T1-weighted structural brain 
scans. Details on study type (single site or multisite), scanner vendor/strength/sequence, 
acquisition parameters and FreeSurfer versions used are provided in supplementary Table 
1s. For quality control, histograms of MOFC thickness values were generated and outliers 
were visually inspected by overlaying their parcellation on the subjects’ anatomical images. 
Only parcellations judged to be accurate upon visual inspection were subjected to statistical 
analyses (see supplementary Table 1s for information on outlier removal and Figure 1s for 
left and right MOFC thickness descriptives by sample). 
 
Statistical analyses 
Within each sample, an association of negative symptoms with left and right MOFC 
thickness was analyzed using univariate linear regression analysis (R’s linear model function 
lm) predicting mean MOFC thickness by global SANS score. The main analysis included age 
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and gender as covariates. In cases of multi-site studies (FBIRN, MCIC, UMCU and Osaka) 
binary dummy covariates were included in the model to account for n−1 sites. For samples 
where information was available, secondary models were run separately with each of the 
following covariates: 1) current antipsychotic medication (by medication group: 
atypical/typical/both/none; and by using chlorpromazine (CPZ) equivalents as described in 
Woods et al. (2003), available in a subsample of n = 1 178), 2) duration of illness, 3) age of 
onset (defined as onset of symptoms), 4) illness severity (measured using PANSS Total 
score), and 5) handedness (right/left/ambidextrous). Additional exploratory analyses were 
carried out to investigate the link between negative symptom severity and cortical thickness 
in schizophrenia spectrum subtypes and in ten additional frontal brain regions. Results were 
ranked according to effect size. In addition, Bonferroni correction was applied to account for 
multiple testing (see SM section 2.2 for more details). Analyses of individual subject data 
were performed by the site that contributed the sample, using code created within the 
ENIGMA collaboration. 
 
Meta-analyses 
From each sample, standardized regression coefficients were extracted from the 
main and secondary models as a measure of effect size for the left and right MOFC using the 
lm.beta function in the lm.beta R package (Behrendt, 2014). A meta-analysis was conducted 
over these effect sizes using the rma function in the R package metaphor (Viechtbauer, 
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2010). We meta-analyzed the estimates across sites by weighting Fisher’s r-to-z transformed 
effect size values by sample size in a random-effects model using the default REML 
estimator. The same procedure was used to investigate the effects of age, gender, illness 
severity and duration of illness on MOFC thickness. For analyses, in which both left and right 
MOFC were analyzed, the significance threshold was corrected for two tests 
(p=0.05/2=0.025). Descriptives are weighted by the sample size at each site using the 
weighted.mean procedure in R (R Development Core Team 2008). 
Due to between-site differences in study characteristics such as antipsychotic 
medication, handedness and single vs multisite status (supplementary Table 1s), we used 
moderator analyses to investigate between-sample differences. 
 
Results 
Demographics 
Mean age (weighted by sample-size) across patient samples was 34 years (range: 28-
43). Mean patient samples were 68% male (range: 55-76%). The weighted mean duration of 
illness across the patient groups was 10 years (range: 1-20) and mean age of onset was 24 
years (range: 19-29). For samples where current antipsychotic type and dose information 
was available, the weighted percentage of patients on first-generation (typical), second-
generation antipsychotics (atypical), both typical and atypical or no antipsychotic 
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medication was 11%, 71%, 9% and 9%. Ninety percent of patients were right-handed (range: 
68-95), while only 8% (range: 2-14) were left-handed and 2% (range: 0-25) were 
ambidextrous (Table 1 and supplementary Table 1s). 
 
Meta-analysis 
The weighted mean global SANS scores across the samples was 7.91 (range: 2.86-
12.90). Weighted mean MOFC thickness was 2.46 mm (range: 2.26-2.71) in the left 
hemisphere and 2.42 mm (range: 2.17-2.61) in the right hemisphere. Meta-analytical results 
showed that global SANS scores were negatively associated with left MOFC thickness (βstd=-
0.075; pSANS=0.019; Figure 1) after accounting for age, gender and number of sites (if 
applicable). Funnel plot inspection gave no indication of bias (Egger’s p=0.193; 
supplementary Figure 2s). However, effect sizes were found to be heterogeneous 
(Q(16)=26.399; p=0.049; I2=42.38%).  We found only a trend effect (but in the same 
direction) of global SANS on right MOFC thickness (βstd=-0.064; pSANS=0.055). For detailed 
results, see supplementary Section 2.1, sections a and b). 
 
Effects of covariates and moderator analyses 
We carried on investigating both within-sample and moderating between-sample 
effects of age, gender, illness severity, duration of illness and age of onset as well as 
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antipsychotic medication, handedness, schizophrenia spectrum subtypes and multisite 
status based on samples, for which this information was available (supplementary Table 1s). 
While a meta-analysis of within-sample effects indicated that left MOFC thickness 
decreased with age (βstd=-0.237; p<0.0001) and was lower in women (βstd=-0.090; 
p<0.0001), the main association of global SANS and left MOFC thickness remained 
significant (βstd=-0.075; pSANS=0.019, see main model above and supplementary section 2.1, 
subsections a, c and d).  
Overall illness severity (although correlated with negative symptoms; R2 = 59.5%) did 
not associate with left MOFC thickness (p=0.555) after accounting for age, gender and site 
(if applicable), while the global SANS effect in the same model remained significant (βstd=-
0.113; pSANS=0.036; see also supplementary section 2.1, subsections e and f).  
Duration of illness correlated negatively with left MOFC thickness (Fisher’s z=-0.145; 
p<0.001), but not with global SANS score (p=0.190). While duration of illness also correlated 
strongly with age (Fisher’s z=0.834; p<0.001), it did not associate with left MOFC thickness 
above and beyond age in the lower regression models (p=0.199). However, additionally 
accounting for duration of illness within each sample also reduced the main effect of SANS 
on left MOFC thickness (pSANS=0.068; see supplementary section 2.1, subsections g and h). 
Similar diminishing effects were observed when investigating the influence of age of onset 
(which was highly correlated with duration of illness; Fisher’s z=-0.658; p=0.015), 
antipsychotic medication and handedness within each sample, which themselves did not 
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moderate the global SANS – left MOFC thickness relationship between samples (pAO=0.737; 
pmed=0.447; phand=0.580; see supplementary section 2.1, section i, j and k). Investigating the 
effects of antipsychotic medication further, we found that mean left MOFC thickness 
estimates (p=0.007), but not mean global SANS estimates (p=0.454) differed by 
antipsychotic medication type (i.e. percentages of patients in each medication group in each 
sample, supplementary section 2.1, subsections l and m). Specifically, compared to 
unmedicated patients, left MOFC reductions were larger at sites with a larger percentage of 
patients treated with atypical (βstd=-0.006; p=0.002) or typical AP (βstd=-0.007; p=0.003). 
Proportion of patients, who were treated with both antipsychotic medication types, was not 
associated with MOFC thickness (p=0.444; supplementary section 2.1, subsection l). The 
reductions observed in patients treated with atypical (but not typical) antipsychotic 
medication remained significant in analyses that included gender, age, or duration of illness 
as covariates (supplementary section 2.1, subsection n and o). Current medication in CPZ 
units was not linked to left MOFC thickness (pCPZ=0.170), while the main effect of negative 
symptom severity remained significant (βstd=-0.095; pSANS=0.040; supplementary section 2.1, 
subsection q and r). Our main findings also remained stable (βstd=-0.078; pSANS=0.022), when 
restricting the analyses to patients with DSM-IV schizophrenia subtypes or schizoaffective / -
phreniform disorder only (supplementary section 2.1, subsection s). 
 
Effect on other frontal regions 
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 Exploratory analyses were used to analyse the associations between negative 
symptoms and ten other frontal brain regions (separately for the left and right hemisphere), 
controlling for sex, age and site (if applicable). Regions with effects similar in size to the left 
MOFC were found in the left pars opercularis (βstd=-0.082), the left and right lateral 
orbitofrontal gyrus (left: βstd=-0.076, right: βstd=-0.073), and the left superiorfrontal gyrus 
(βstd=-0.066). After Bonferroni correction for multiple testing, two regions – the left lateral 
orbitofrontal gyrus (corrected pSANS=0.034) and left the pars opercularis (corrected 
pSANS=0.02) - remained significant (SM section 2.2). The direction, size and lateralization of 
the effect compared well to our main results. 
 
Discussion 
Summary 
 In this study, we investigated the relationship between MOFC thinning and negative 
symptom severity in schizophrenia. We found that negative symptoms related inversely to 
cortical thickness in this brain region, with effects appearing greater in the left hemisphere 
compared to the right. This finding was independent of general illness severity, age and 
gender, but somewhat lessened when covarying for the influence of antipsychotic 
medication, age of onset and duration of illness (with the latter two variables being highly 
correlated). Exploratory analyses identified associations between negative symptoms and 
Walton et al.                                                                           Negative symptoms and cortical thinning 
 
22 
 
thickness in the lateral orbitofrontal gyrus and pars opercularis in the left hemisphere. Our 
investigation has a number of strengths. First, using a meta-analytical approach, we were 
able to increase our sample size by a magnitude of 10 compared to previous studies. 
Second, the large sample allowed for the investigation of potentially influencing, but small 
effects of age, gender, illness severity, duration of illness, age of onset, antipsychotic 
medication, and handedness. Third, our sample included diverse patient groups that spans a 
broad age range allowing for a generalization of our findings. 
 
Cortical thickness in the left medial orbitofrontal cortex and negative symptoms 
 Our results are in agreement with two previously published studies. Specifically, the 
association between MOFC thickness and negative symptoms in the study by 
Venkatasubramanian et al. (2008) was also negative and only present in the left 
hemisphere. Comparing patient groups with distinct symptom profiles, the study by Nenadic 
et al. (2015) also reported prefrontal reductions (including the MOFC) in patients 
characterized by predominantly negative symptoms compared to subgroups with 
predominantly paranoid and disorganised symptoms. However, there have also been 
reports, which failed to identify an association between MOFC thickness and negative 
symptoms (Xiao et al. 2013; Bodnar et al. 2014; Ansell et al. 2015; McKechanie et al. 2015). 
There are several potential explanations for these discrepant findings. First, all previous 
studies were based on rather small samples (between 40 and 130 patients) and hence 
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potentially underpowered to detect the weak, but robust association, we were able to 
identify in our study based on almost 2 000 patients. Furthermore, previous samples 
differed substantially in important characteristics such as illness chronicity and mean age. Of 
note, all studies that accepted the null hypothesis consisted of young (< 25 years), first-
episode patients, while studies which reported effects, such as by Venkatasubramanian et 
al. (2008) and Nenadic et al. (2015), included older (>30 years), chronic patients. Similarly, 
mean age across our samples ranged from 28 – 43 years while mean duration of illness was 
10 years, indicating that the association between negative symptoms and MOFC thickness 
might be more apparent when patients are older or in later stages of the disorder. 
Animal and human studies suggest that neurons in the MOFC encode the subjective 
value of expected reward (Furuyashiki & Gallagher, 2007; Roesch & Olson, 2007), providing 
evidence that the MOFC mediates processes associated with the learning and retrieval of 
(subjective) value information, which guides decision-making and goal-directed behaviour 
(Bechara et al. 1994, 2000). Several studies suggest that negative symptoms in 
schizophrenia are associated with reinforcement learning abnormality (Waltz et al. 2007; 
Strauss et al. 2011). Gold et al. (2012) observed that patients with high-negative symptoms 
were less able to take expected reward values into account during decision making 
processes. As a result, patients fail to learn actions that lead to positive outcomes, while 
they outperform controls in avoiding punishing outcomes, showing that the findings were 
not indicative of general learning deficits, but of deficits in reward-related learning. Such 
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findings may help to explain the high prevalence of avolition and anhedonia in 
schizophrenia, two core dimensions of negative symptomatology. In line with this, aberrant 
neural responses to reward feedback was observed in medial prefrontal areas of patients 
with schizophrenia (Schlagenhauf et al. 2009), although results from this and several other 
studies also emphasize the relevance of ventral striatal pathways pointing towards an 
involvement of a wider striatal-prefrontal network in reward feedback (Schlagenhauf et al. 
2014; Mørch-Johnsen et al. 2015; Radua et al. 2015).  
The involvement of additional frontal brain regions is also supported by the results 
of our study, as exploratory analyses showed further associations of negative symptoms 
with the left lateral orbitofrontal gyrus and left pars opercularis. In line with our initial 
hypothesis, the lateral orbitofrontal gyrus is also predominantly involved in value processing 
(Kringelbach & Rolls, 2004; Zald et al. 2014). The pars opercularis is mainly linked to 
language processing (Belyk & Brown, 2014), which might relate to poverty of speech. An 
association of comparable effect size to our main finding, but not significant after 
Bonferroni correction, was also identified in the superior frontal gyrus (including the pre-
supplementary motor area that is involved in volition (Haggard 2008; Bracht et al. 2013)), 
which might be associated with the lack of ability for spontaneous, self-generated action 
that relates strongly to the avolition subdomain of negative symptoms. 
We observed a significant association between grey matter thickness and negative 
symptoms only in the left hemisphere. This aligns well with several other reports of 
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significant grey matter reductions in frontal regions of the left hemisphere (but not the right 
hemisphere) in patients with schizophrenia ( Suzuki et al. 2002; Kawasaki et al. 2004; Honea 
et al. 2005; Kawasaki et al. 2008;). Moreover, cerebral lateralization of patients with 
schizophrenia tends to be less leftward lateralized and may even be rightward lateralized 
rather than symmetric. While some have argued that this might possibly reflect 
perturbations in the lateralization process underlying left cerebral dominance for language 
(Kawasaki et al. 2008), others believe that this atypical lateralization represents a greater 
involvement of the right hemisphere, which may relate to a broader, more diffuse semantic 
network (Grabner et al. 2007). With respect to value processing, the left prefrontal cortex 
has been linked stronger to motivation and positive affect than the right (Davidson, 2004; 
Price & Harmon-Jones, 2011). Hence, structural abnormalities in this region could link to 
deficits in the capacity to experience positive affect, a hallmark feature of negative 
symptoms. 
In sum, our finding of a negative association between left MOFC thickness and 
negative symptoms underline the importance of this region in motivational and executive 
functioning, which is commonly impaired in schizophrenia patients (Barch & Dowd, 2010).  
 
Potential moderators 
Illness severity 
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 We found that the effect of negative symptoms on left MOFC thickness was 
independent of general illness severity. That is, the MOFC might be specifically involved in 
motivational and executive aspects of schizophrenia as opposed to general schizophrenia 
psychopathology. Two other cortical thickness studies also failed to identify a significant 
correlation between illness severity (as measured using PANSS total scores) and thickness in 
any cortical region (Rimol et al. 2010; Oertel-Knöchel et al. 2013). Furthermore, van Haren 
et al. (2011) identified an association between poor functional and symptomatic outcome 
(derived using a factor analysis on Global Assessment of Functioning (GAF), the Camberwell 
Assessment of Need scale, and PANSS) and cortical thinning in the superior temporal gyrus, 
but not in frontal areas. Also in line with this is a functional imaging study by Simon et al. 
(2015), who investigated whole-brain activation during a reward anticipation paradigm. The 
authors observed that negative symptoms (especially signs of apathy), but not positive 
symptoms, were inversely correlated with activation in the ventral striatum, which at the 
same time showed reduced connectivity with the MOFC in patients compared to controls, 
further supporting the role of the MOFC in negative symptoms in schizophrenia. 
 
Duration of illness 
 Duration of illness correlated strongly and negatively with left MOFC thickness (but 
not with negative symptom scores), although effects were dependent on age effects on 
thickness. Negative symptoms no longer predicted thickness significantly when covarying 
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for age and duration of illness (which was highly correlated with age and not predictive of 
MOFC thickness in the combined model) in the same model. This may indicate that some of 
the variance in thickness explained by negative symptoms depends on these variables. In 
this respect and as explained above, it is of interest that studies of first-episode patients did 
not find an association between symptoms and thickness in the MOFC. Ansell et al. (2015) 
studied very young (mean age of 22 years) psychosis patients, who had been diagnosed for 
the first time within the last three months. The authors found no effects of negative 
symptoms on thickness in prefrontal areas (although they did report that negative 
symptoms related to reduced thickness in parietal regions, but only in patients treated with 
first-generation antipsychotics). Crespo-Facorro et al. (2011) also studied first-episode 
patients and reported no significant relationship between negative symptoms and lobar 
cortical thickness. In the light of these previous findings and considering that participants in 
our study were predominantly older, chronic patients, our results might be more specific to 
later stages of the disorder. 
 
Antipsychotic medication 
 Although the relationship between negative symptoms and left MOFC thickness did 
not vary by antipsychotic medication group in our moderator analysis, some amount of 
variance in left MOFC thickness was explained through antipsychotic medication effects, 
with patients treated with atypical antipsychotics showing the most robust reductions. 
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Notably, when we used current medication in CPZ equivalent units as a quantitative 
measures of antipsychotic medication (at the cost of a reduced sample size), an effect on 
MOFC thickness was not observed. While past studies predominantly reported volume and 
thickness deficits in frontal brain regions in patients treated with typical compared to those 
treated with atypical antipsychotics or unmedicated patients (van Haren et al. 2011; Lesh et 
al. 2015; Vita et al. 2015), there have also been many conflicting findings (Cahn et al. 2002; 
Ho et al. 2011). Attempting to reconcile previous reports, it has been suggested that 
antipsychotic medication effects on brain structure might be substance-specific (Xiao et al. 
2008) and might also depend on illness chronicity and the duration of untreated psychosis. 
Some studies reported that medication effects on frontal brain structures were apparent 
especially during the early phase of treatment and that the effect size increased with longer 
durations of untreated psychosis (for a review see (Aderhold et al. 2014)). Genetic 
predisposition and substance use could also interact with antipsychotic medication 
(Tregellas et al. 2007; Hartz et al. 2010). With respect to our own findings we would like to 
stress that this is a purely correlational result, which does not in any way imply a causal 
relationship between antipsychotic medication intake and cortical thinning. Considering that 
we only investigated the possible effect of current antipsychotic medication, future studies 
are necessary to investigate this relationship in more detail by studying estimates of 
cumulative antipsychotic medication such as equivalent dose by time of exposure or 
treatment intensity in dose-years (Andreasen et al. 2010, 2013). 
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Limitations 
 The results of this study have to be seen in the light of the following limitations. First, 
our study was strongly hypothesis-driven in that we focussed on effects in the medial 
orbitofrontal cortex due to its role in value processing. As part of our exploratory analyses 
we also identified associations of comparable effect size in other brain regions including the 
pars opercularis and lateral orbitofrontal gyrus. Further studies are needed to investigate 
whether these associations are driven by processes that are not directly linked to value 
processing. Secondly, given the cross-sectional design of this study, we were unable to 
address directional effects. That is, we were not able to determine whether cortical thinning 
precedes or follows the development of negative symptoms. A range of factors such as 
measures of cumulative antipsychotic medication or relapse duration (Andreasen et al. 
2010, 2013), which we were unable to investigate, might modulate the observed association 
and should be investigated in subsequent studies. Third, we included patients within the 
schizophrenia spectrum and used a measure of global negative symptom severity, but it is 
possible that effects were driven by schizophrenia subtype or subdimension-specific 
characteristics. 
 
Conclusion 
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 We investigated the relationship between negative symptoms and cortical thickness 
in the medial orbitofrontal cortex in a large cohort of schizophrenia patients, comprising 
almost 2 000 patients. Negative symptom severity was significantly associated with 
thickness in this region in the left, but not the right hemisphere. This association was 
irrespective of age, gender and illness severity, but possibly modulated by antipsychotic 
medication and duration of illness. Our findings provide further insight into symptom-
related pathophysiological processes of schizophrenia.  
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Table 
  estimate range data available for N 
number of studies 
% males 68 55-76 17 
Mean age in years 34 28-43 17 
Mean SANS Global 7.91 2.86-12.90 17 
Mean duration of illness in years 10 1-20 13 
Mean Age of Onset in years 24 19-29 13 
Mean illness severity (PANSS Total) 70.43 49.81-90.22 9 
Antipsychotic medication   13 
    %Atypical (N) 71 (1201) 39-91  
    %Typical (N) 11 (202) 0-45  
    %Both A & T (N) 9 (157) 0-24  
    %None (N) 9 (149) 0-53   
Mean Chlorpromazine equivalents 423.32 97.48-637.80 12 
Handedness   14 
    %Right 90 68-95  
    %Left 8 2-14  
    %Ambidextrous 2 0-25   
Cortical thickness in mm   17 
    Mean left medial orbitofrontal  2.46 2.26-2.71  
    Mean right medial orbitofrontal  2.42 2.17-2.61  
 
Table 1. Demographics. Means are weighted by study sample size. 
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Figure legend 
Figure 1. Forest plot of association between global SANS and cortical thickness in the left 
medial orbitofrontal cortex across all 17 study sites, controlling for age, gender and number 
of sites (if applicable; of note the global SANS-left MOFC thickness relationship did not differ 
between single vs multisite samples (p=0.422; see supplementary section 2.1, subsection 
o)). Fisher’s transformed standardized regression coefficients are denoted by black boxes. 
Black lines indicate 95% confidence intervals. The combined estimate for all sites is 
represented by a black diamond with the outer edges of the diamond indicating the 
confidence interval limits. 
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Supplementary Materials 
 
SM 1 Method 
 
SM 1.1 Symptom score conversion algorithms 
 
Global SANS (Summary) Score = -2.0671 + (0.665*PANSS Negative score) 
Global SANS (Summary) Score = 1.0863 + (0.2943*Total SANS (composite) score) 
 
SM 1.2 Imaging descriptives and quality control 
Parcellations were visually inspected and statistically evaluated for outliers following 
standardized ENIGMA protocols (http://enigma.ini.usc.edu/protocols/imaging-protocols). Each 
image parcellation was individually examined by a neuroimaging expert at each site by overlaying 
the parcellation label of each structure on the T1-weighted brain scan. Further, we collected study-
wide statistics (means, minimums, maximums, and standard deviations; see SM Figure 1s) as well as 
histogram and diagnostic plots in order to identify non-normally distributed data and major outliers. 
A subject was considered a statistical outlier if its thickness was >2.698 standard deviations away 
from the global mean. For each subject that was marked as a statistical outlier, individual sites were 
asked to re-inspect the subject’s parcellations in order to verify that it was properly segmented. If a 
subject was a statistical outlier, but was properly segmented it was kept in the analysis. Otherwise 
the subject was removed (see SM Table 2s for details). 
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SM Figure 1s. Left (A-B) and right (C-D) medial orbitofrontal cortical thickness descriptives 
(min/mean/sd/max) by study site. 
 
 
SM 2 Results 
SM 2.1 Detailed results of meta-analyses 
a) Main model: left MOFC <- global SANS + gender + age + site (if applicable) 
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In the main model we investigated the effect of global SANS scores on left MOFC thickness, 
covarying for gender, age and the number of sites as dummy variables (where applicable). 
Shown below are the estimate, the standard error, p value and the confidence intervals for the 
meta-analytical standardized regression beta of the global SANS score on left MOFC thickness. 
Results were based on estimates from 17 studies using a restricted maximum likelihood (REML) 
approach. Also provided are estimates and significance levels for effect size heterogeneity 
between studies. 
Random-Effects Model (k = 17; tau^2 estimator: REML) 
 
tau^2 (estimated amount of total heterogeneity): 0.0067 (SE = 
0.0057) 
tau (square root of estimated tau^2 value):      0.0816 
I^2 (total heterogeneity / total variability):   42.38% 
H^2 (total variability / sampling variability):  1.74 
 
Test for Heterogeneity:  
Q(df = 16) = 26.3994, p-val = 0.0487 
 
Model Results: 
 
estimate       se     zval     pval    ci.lb    ci.ub           
 -0.0752   0.0321  -2.3446   0.0190  -0.1381  -0.0123        *  
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Funnel plot main model 
 
SM Figure 2s. Funnel plot. Individual study regression coefficients are plotted against sample 
variance (a measure of the precision of the data).  
 
b) Exploratory model: right MOFC <- global SANS + gender + age + site (if applicable) 
 
Shown below are the estimate, the standard error, p value and the confidence intervals for the 
meta-analytical standardized regression beta of the global SANS score on right MOFC thickness. 
Results were based on estimates from 17 studies. 
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Random-Effects Model (k = 17; tau^2 estimator: REML) 
 
tau^2 (estimated amount of total heterogeneity): 0.0080 (SE = 
0.0063) 
tau (square root of estimated tau^2 value):      0.0892 
I^2 (total heterogeneity / total variability):   46.78% 
H^2 (total variability / sampling variability):  1.88 
 
Test for Heterogeneity:  
Q(df = 16) = 28.4025, p-val = 0.0283 
 
Model Results: 
 
estimate       se     zval     pval    ci.lb    ci.ub           
 -0.0643   0.0335  -1.9207   0.0548  -0.1299   0.0013        .  
 
 
c) Effects of covariates: left MOFC <- global SANS + gender + age + site (if applicable) 
 
Shown below are the estimate, the standard error, p value and the confidence intervals for the 
meta-analytical standardized regression beta of age on left MOFC thickness. Results were based 
on estimates from 17 studies. 
Random-Effects Model (k = 17; tau^2 estimator: REML) 
 
tau^2 (estimated amount of total heterogeneity): 0.0117 (SE = 
0.0078) 
tau (square root of estimated tau^2 value):      0.1083 
I^2 (total heterogeneity / total variability):   56.43% 
H^2 (total variability / sampling variability):  2.30 
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Test for Heterogeneity:  
Q(df = 16) = 36.1039, p-val = 0.0028 
 
Model Results: 
 
estimate       se     zval     pval    ci.lb    ci.ub           
 -0.2372   0.0371  -6.3925   <.0001  -0.3100  -0.1645      ***  
 
d) Effects of covariates: left MOFC <- global SANS + gender + age + site (if applicable) 
 
Shown below are the estimate, the standard error, p value and the confidence intervals 
for the meta-analytical standardized regression beta of gender on left MOFC thickness. 
Results were based on estimates from 17 studies. 
Random-Effects Model (k = 17; tau^2 estimator: REML) 
 
tau^2 (estimated amount of total heterogeneity): 0 (SE = 
0.0026) 
tau (square root of estimated tau^2 value):      0 
I^2 (total heterogeneity / total variability):   0.00% 
H^2 (total variability / sampling variability):  1.00 
 
Test for Heterogeneity:  
Q(df = 16) = 13.5923, p-val = 0.6291 
 
Model Results: 
 
estimate       se     zval     pval    ci.lb    ci.ub           
 -0.0900   0.0227  -3.9592   <.0001  -0.1346  -0.0455      *** 
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e) Effects of covariates: left MOFC <- global SANS + illness severity + gender + age + site (if 
applicable) 
 
Shown below are the estimate, the standard error, p value and the confidence intervals 
for the meta-analytical standardized regression beta of illness severity on left MOFC 
thickness. Results were based on estimates from 9 studies. 
Random-Effects Model (k = 9; tau^2 estimator: REML) 
 
tau^2 (estimated amount of total heterogeneity): 0.0387 (SE = 
0.0254) 
tau (square root of estimated tau^2 value):      0.1967 
I^2 (total heterogeneity / total variability):   81.26% 
H^2 (total variability / sampling variability):  5.34 
 
Test for Heterogeneity:  
Q(df = 8) = 44.9511, p-val < .0001 
 
Model Results: 
 
estimate       se     zval     pval    ci.lb    ci.ub           
  0.0446   0.0755   0.5908   0.5546  -0.1034   0.1927           
 
 
f) Effects of covariates: left MOFC <- global SANS + illness severity + gender + age + site (if 
applicable) 
 
Shown below are the estimate, the standard error, p value and the confidence intervals 
for the meta-analytical standardized regression beta of global SANS score on left MOFC 
thickness. Results were based on estimates from 9 studies. 
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Random-Effects Model (k = 9; tau^2 estimator: REML) 
 
tau^2 (estimated amount of total heterogeneity): 0.0145 (SE = 
0.0126) 
tau (square root of estimated tau^2 value):      0.1205 
I^2 (total heterogeneity / total variability):   61.91% 
H^2 (total variability / sampling variability):  2.63 
 
Test for Heterogeneity:  
Q(df = 8) = 21.8200, p-val = 0.0053 
 
Model Results: 
 
estimate       se     zval     pval    ci.lb    ci.ub           
 -0.1126   0.0536  -2.0998   0.0357  -0.2177  -0.0075        *  
 
g) Effects of covariates: left MOFC <- global SANS + length of illness + gender + age + site (if 
applicable) 
 
Shown below are the estimate, the standard error, p value and the confidence intervals 
for the meta-analytical standardized regression beta of length of illness estimates on left 
MOFC thickness. Results were based on estimates from 13 studies. 
Random-Effects Model (k = 13; tau^2 estimator: REML) 
 
tau^2 (estimated amount of total heterogeneity): 0.0539 (SE = 
0.0271) 
tau (square root of estimated tau^2 value):      0.2321 
I^2 (total heterogeneity / total variability):   86.66% 
H^2 (total variability / sampling variability):  7.50 
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Test for Heterogeneity:  
Q(df = 12) = 51.8783, p-val < .0001 
 
Model Results: 
 
estimate       se     zval     pval    ci.lb    ci.ub           
 -0.0922   0.0719  -1.2836   0.1993  -0.2331   0.0486  
 
h) Effects of covariates: left MOFC <- global SANS + length of illness + gender + age + site (if 
applicable) 
 
Shown below are the estimate, the standard error, p value and the confidence intervals 
for the meta-analytical standardized regression beta of global SANS scores on left MOFC 
thickness. Results were based on estimates from 13 studies. 
Random-Effects Model (k = 13; tau^2 estimator: REML) 
 
tau^2 (estimated amount of total heterogeneity): 0.0079 (SE = 
0.0069) 
tau (square root of estimated tau^2 value):      0.0892 
I^2 (total heterogeneity / total variability):   48.94% 
H^2 (total variability / sampling variability):  1.96 
 
Test for Heterogeneity:  
Q(df = 12) = 22.8334, p-val = 0.0292 
 
Model Results: 
 
estimate       se     zval     pval    ci.lb    ci.ub           
 -0.0681   0.0373  -1.8240   0.0682  -0.1413   0.0051        .  
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i) Moderation analysis of age of onset on the association between global SANS scores and 
left MOFC thickness 
 
Shown below are the estimate, the standard error, p value and the confidence intervals 
for the moderating effects of age of onset on the meta-analytical standardized 
regression beta of global SANS scores on left MOFC thickness. Results were based on 
estimates from 13 studies. 
Mixed-Effects Model (k = 13; tau^2 estimator: REML) 
 
tau^2 (estimated amount of residual heterogeneity):     0.0077 (SE = 0.0072) 
tau (square root of estimated tau^2 value):             0.0875 
I^2 (residual heterogeneity / unaccounted variability): 46.82% 
H^2 (unaccounted variability / sampling variability):   1.88 
R^2 (amount of heterogeneity accounted for):            0.00% 
 
Test for Residual Heterogeneity:  
QE(df = 11) = 20.0562, p-val = 0.0446 
 
Test of Moderators (coefficient(s) 2):  
QM(df = 1) = 0.1133, p-val = 0.7365 
 
Model Results: 
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                                 se     zval    pval    ci.lb   ci.ub    
intrcpt             -0.0651  0.0370  -1.7578  0.0788  -0.1377  0.0075  . 
I(AO_mean - 23.83)   0.0050  0.0149   0.3365  0.7365  -0.0242  0.0342 
 
 
j) Moderation analysis of antipsychotic medication on the association between global 
SANS scores and left MOFC thickness 
 
To investigate potentially moderating effects of antipsychotic medication, we derived 
the percentages of patients treated with typical or atypical antipsychotics, both 
antipsychotic medication types and the percentage of unmedicated patients in each 
sample. Shown below are the estimate, the standard error, p value and the confidence 
intervals for the moderating effects of antipsychotic medication on the meta-analytical 
standardized regression beta of global SANS scores on left MOFC thickness. Percentages 
of participants on typical, atypical and combined antipsychotic medication were mean 
centered and compared to the percentage of unmedicated patients (baseline). The 
intercept refers to the effect of global SANS score on left MOFC thickness after 
accounting for antipsychotic medication. Results were based on estimates from 13 
studies. 
 
Mixed-Effects Model (k = 13; tau^2 estimator: REML) 
 
tau^2 (estimated amount of residual heterogeneity):     0.0039 (SE = 
0.0056) 
tau (square root of estimated tau^2 value):             0.0621 
I^2 (residual heterogeneity / unaccounted variability): 32.04% 
H^2 (unaccounted variability / sampling variability):   1.47 
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R^2 (amount of heterogeneity accounted for):            0.00% 
 
Test for Residual Heterogeneity:  
QE(df = 9) = 11.9256, p-val = 0.2175 
 
Test of Moderators (coefficient(s) 2,3,4):  
QM(df = 3) = 2.6632, p-val = 0.4465 
 
Model Results: 
 
                      estimate      se     zval    pval    ci.lb   ci.ub    
intrcpt                -0.0489  0.0318  -1.5375  0.1242  -0.1112  0.0134    
I(MED_a_perc - 68.72)   0.0042  0.0031   1.3557  0.1752  -0.0019  0.0103    
I(MED_b_perc - 8.536)   0.0009  0.0048   0.1812  0.8562  -0.0086  0.0103    
I(MED_t_perc - 11.1)    0.0022  0.0038   0.5879  0.5566  -0.0052  0.0097    
 
N.B.: predictor abbreviations refer to percentage of patients treated with atypical (MED_a_perc) or 
typical (MED_t_perc) antipsychotics, both antipsychotic medication types (MED_b_perc) and the 
percentage of unmedicated patients (intrcpt, i.e. baseline). 
 
k) Moderation analysis of handedness on the association between global SANS scores and 
left MOFC thickness 
 
To investigate potentially moderating effects of handedness, we derived the percentage 
of ambidextrous, left- and right-handed participants. Shown below are the estimate, the 
standard error, p value and the confidence intervals for the moderating effects of 
handedness on the meta-analytical standardized regression beta of global SANS scores 
on left MOFC thickness. Percentages of ambidextriuos and left-handed partipicants were 
mean centered and compared to the right-handed group (baseline). The intercept refers 
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to the effect of global SANS score on left MOFC thickness after accounting for 
handedness. Results were based on estimates from 14 studies. 
Mixed-Effects Model (k = 14; tau^2 estimator: REML) 
 
tau^2 (estimated amount of residual heterogeneity):     0.0061 (SE = 
0.0059) 
tau (square root of estimated tau^2 value):             0.0780 
I^2 (residual heterogeneity / unaccounted variability): 44.65% 
H^2 (unaccounted variability / sampling variability):   1.81 
R^2 (amount of heterogeneity accounted for):            0.00% 
 
Test for Residual Heterogeneity:  
QE(df = 11) = 19.0779, p-val = 0.0597 
 
Test of Moderators (coefficient(s) 2,3):  
QM(df = 2) = 1.0884, p-val = 0.5803 
 
Model Results: 
 
                       estimate      se     zval    pval    ci.lb   ci.ub    
intrcpt                 -0.0603  0.0342  -1.7634  0.0778  -0.1273  0.0067  
. 
I(HAND_a_perc - 3.591)   0.0010  0.0074   0.1399  0.8888  -0.0134  0.0154    
I(HAND_l_perc - 8.688)  -0.0113  0.0116  -0.9744  0.3299  -0.0341  0.0115    
N.B.: predictor abbreviations refer to the percentage of ambidextrous (HAND_a_perc), left-handed 
(HAND_l_perc) and right-handed patients (intrcpt, i.e. baseline). 
 
l) Left MOFC thickness differences by antipsychotic medication type percentages 
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We also investigated whether left MOFC thickness differed by the percentage of 
patients treated with typical or atypical antipsychotics, both antipsychotic medication 
types and the percentage of unmedicated patients. Shown below are the estimate, the 
standard error, p value and the confidence intervals of mean left MOFC thickness for 
each antipsychotic medication group. Percentages were mean centered and compared 
to unmedicated patients (baseline). Results were based on estimates from 13 studies. 
Mixed-Effects Model (k = 13; tau^2 estimator: REML) 
 
tau^2 (estimated amount of residual heterogeneity):     0.0060 (SE = 0.0030) 
tau (square root of estimated tau^2 value):             0.0777 
I^2 (residual heterogeneity / unaccounted variability): 95.96% 
H^2 (unaccounted variability / sampling variability):   24.73 
R^2 (amount of heterogeneity accounted for):            44.87% 
 
Test for Residual Heterogeneity:  
QE(df = 9) = 249.4885, p-val < .0001 
 
Test of Moderators (coefficient(s) 2,3,4):  
QM(df = 3) = 12.2740, p-val = 0.0065 
 
Model Results: 
 
                      estimate        se     zval    pval    ci.lb   ci.ub    
intrcpt                 2.4841  0.0222  111.8192  <.0001   2.4405   2.5276  
*** 
I(MED_a_perc - 68.72)  -0.0058  0.0019   -3.1327  0.0017  -0.0094  -0.0022   
** 
I(MED_b_perc - 8.536)  -0.0026  0.0033   -0.7653  0.4441  -0.0091   0.0040      
I(MED_t_perc - 11.1)   -0.0065  0.0022   -2.9253  0.0034  -0.0109  -0.0021   
** 
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N.B.: predictor abbreviations refer to percentage of patients treated with atypical (MED_a_perc) or 
typical (MED_t_perc) antipsychotics, both antipsychotic medication types (MED_b_perc) and the 
percentage of unmedicated patients (intrcpt, i.e. baseline). 
 
m) Global SANS score differences by antipsychotic medication type percentages 
 
Furthermore, We also investigated whether global SANS scores differed by the 
percentage of patients treated with typical or atypical antipsychotics, both antipsychotic 
medication types and the percentage of unmedicated patients. Shown below are the 
estimate, the standard error, p value and the confidence intervals of mean global SANS 
scores for each antipsychotic medication group. Percentages were mean centered and 
compared to unmedicated patients (baseline). Results were based on estimates from 13 
studies. 
Mixed-Effects Model (k = 13; tau^2 estimator: REML) 
 
tau^2 (estimated amount of residual heterogeneity):     7.3158 (SE = 3.5444) 
tau (square root of estimated tau^2 value):             2.7048 
I^2 (residual heterogeneity / unaccounted variability): 98.34% 
H^2 (unaccounted variability / sampling variability):   60.25 
R^2 (amount of heterogeneity accounted for):            0.00% 
 
Test for Residual Heterogeneity:  
QE(df = 9) = 483.0582, p-val < .0001 
 
Test of Moderators (coefficient(s) 2,3,4):  
QM(df = 3) = 2.6231, p-val = 0.4535 
 
Model Results: 
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                      estimate      se     zval    pval    ci.lb    ci.ub      
intrcpt                 8.7936  0.7616  11.5460  <.0001   7.3009  10.2863  
*** 
I(MED_a_perc - 68.72)  -0.0229  0.0627  -0.3648  0.7153  -0.1457   0.1000      
I(MED_b_perc - 8.536)   0.1342  0.1142   1.1748  0.2401  -0.0897   0.3581      
I(MED_t_perc - 11.1)   -0.0591  0.0758  -0.7793  0.4358  -0.2078   0.0895      
N.B.: predictor abbreviations refer to percentage of patients treated with atypical (MED_a_perc) or 
typical (MED_t_perc) antipsychotics, both antipsychotic medication types (MED_b_perc) and the 
percentage of unmedicated patients (intrcpt, i.e. baseline). 
 
n) Left MOFC thickness differences by antipsychotic medication type percentages, 
covarying for gender and age 
 
We also investigated whether left MOFC thickness differed by the percentage of 
patients treated with typical or atypical antipsychotics, both antipsychotic medication 
types and the percentage of unmedicated patients, when additionally controlling for 
gender and age. Shown below are the estimate, the standard error, p value and the 
confidence intervals of mean left MOFC thickness for each antipsychotic medication 
group. Percentages were mean centered and compared to unmedicated patients 
(baseline). Results were based on estimates from 13 studies. 
 
Mixed-Effects Model (k = 13; tau^2 estimator: REML) 
 
tau^2 (estimated amount of residual heterogeneity):     0.0076 (SE = 0.0043) 
tau (square root of estimated tau^2 value):             0.0873 
I^2 (residual heterogeneity / unaccounted variability): 96.44% 
H^2 (unaccounted variability / sampling variability):   28.06 
R^2 (amount of heterogeneity accounted for):            30.46% 
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Test for Residual Heterogeneity:  
QE(df = 7) = 235.2282, p-val < .0001 
 
Test of Moderators (coefficient(s) 2,3,4,5,6):  
QM(df = 5) = 10.1896, p-val = 0.0700 
 
Model Results: 
 
                      estimate      se     zval    pval    ci.lb    ci.ub      
intrcpt                 2.4799  0.0267  92.8312  <.0001   2.4276   2.5323  
*** 
I(Age_mean - 34.72)    -0.0041  0.0100  -0.4115  0.6807  -0.0237   0.0155      
I(MED_a_perc - 68.72)  -0.0056  0.0022  -2.5524  0.0107  -0.0098  -0.0013    
* 
I(MED_b_perc - 8.536)  -0.0016  0.0046  -0.3361  0.7368  -0.0106   0.0075      
I(MED_t_perc - 11.1)   -0.0053  0.0035  -1.5391  0.1238  -0.0121   0.0015      
I(MF_ratio - 2.255)    -0.0091  0.0386  -0.2365  0.8130  -0.0848   0.0666      
N.B.: predictor abbreviations refer to percentage of patients treated with atypical (MED_a_perc) or 
typical (MED_t_perc) antipsychotics, both antipsychotic medication types (MED_b_perc) and the 
percentage of unmedicated patients (intrcpt, i.e. baseline) as well as the ratio of males versus 
females (MF_ratio). 
 
o) Left MOFC thickness differences by antipsychotic medication type percentages, 
covarying for gender and length of illness 
 
We also investigated whether left MOFC thickness differed by the percentage of 
patients treated with typical or atypical antipsychotics, both antipsychotic medication 
types and the percentage of unmedicated patients, when additionally controlling for 
gender and length of ilness. Shown below are the estimate, the standard error, p value 
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and the confidence intervals of mean left MOFC thickness for each antipsychotic 
medication group. Percentages were mean centered and compared to unmedicated 
patients (baseline). Results were based on estimates from 11 studies. 
Mixed-Effects Model (k = 11; tau^2 estimator: REML) 
 
tau^2 (estimated amount of residual heterogeneity):     0.0087 (SE = 0.0057) 
tau (square root of estimated tau^2 value):             0.0932 
I^2 (residual heterogeneity / unaccounted variability): 97.07% 
H^2 (unaccounted variability / sampling variability):   34.16 
R^2 (amount of heterogeneity accounted for):            31.69% 
 
Test for Residual Heterogeneity:  
QE(df = 5) = 187.9049, p-val < .0001 
 
Test of Moderators (coefficient(s) 2,3,4,5,6):  
QM(df = 5) = 9.6171, p-val = 0.0868 
 
Model Results: 
 
                      estimate      se     zval    pval    ci.lb    ci.ub      
intrcpt                 2.4693  0.0348  70.9461  <.0001   2.4011   2.5376  
*** 
I(LOI_mean - 10.74)    -0.0077  0.0119  -0.6514  0.5148  -0.0310   0.0155      
I(MED_a_perc - 68.72)  -0.0051  0.0025  -2.0599  0.0394  -0.0100  -0.0002    
* 
I(MED_b_perc - 8.536)   0.0013  0.0074   0.1793  0.8577  -0.0132   0.0159      
I(MED_t_perc - 11.1)   -0.0042  0.0036  -1.1451  0.2522  -0.0113   0.0030      
I(MF_ratio - 2.255)     0.0089  0.0644   0.1384  0.8899  -0.1172   0.1350      
N.B.: predictor abbreviations refer to percentage of patients treated with atypical (MED_a_perc) or 
typical (MED_t_perc) antipsychotics, both antipsychotic medication types (MED_b_perc) and the 
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percentage of unmedicated patients (intrcpt, i.e. baseline) as well as the ratio of males versus 
females (MF_ratio) and mean length of illness (LOI_mean). 
 
 
p) Moderation analysis of single vs multisite status on the association between global SANS 
scores and left MOFC thickness 
 
Shown below are the estimate, the standard error, p value and the confidence intervals for the 
moderating effects of single vs multisite status on the meta-analytical standardized regression 
beta of global SANS scores on left MOFC thickness. The intercept refers to the effect of global 
SANS score on left MOFC thickness after accounting for single vs multisite status. Results were 
based on estimates from 17 studies. 
Mixed-Effects Model (k = 17; tau^2 estimator: REML) 
 
tau^2 (estimated amount of residual heterogeneity):     0.0078 (SE = 
0.0066) 
tau (square root of estimated tau^2 value):             0.0886 
I^2 (residual heterogeneity / unaccounted variability): 45.43% 
H^2 (unaccounted variability / sampling variability):   1.83 
R^2 (amount of heterogeneity accounted for):            0.00% 
 
Test for Residual Heterogeneity:  
QE(df = 15) = 25.9669, p-val = 0.0384 
 
Test of Moderators (coefficient(s) 2):  
QM(df = 1) = 0.6443, p-val = 0.4222 
 
Model Results: 
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                      estimate      se     zval    pval    ci.lb    ci.ub    
intrcpt                -0.0954  0.0409  -2.3295  0.0198  -0.1756  -0.0151  
* 
as.factor(multisite)1   0.0567  0.0706   0.8027  0.4222  -0.0817   0.1950    
 
q) Effects of covariates: left MOFC <- global SANS + CPZ + gender + age + site (if applicable) 
 
Shown below are the estimate, the standard error, p value and the confidence intervals 
for the meta-analytical standardized regression beta of current chlorpromazine 
equivalents (CPZ, based on Woods et al. (2003)) on left MOFC thickness. Results were 
based on estimates from 12 studies. 
 
Random-Effects Model (k = 12; tau^2 estimator: REML) 
 
tau^2 (estimated amount of total heterogeneity): 0.0003 (SE = 
0.0040) 
tau (square root of estimated tau^2 value):      0.0160 
I^2 (total heterogeneity / total variability):   2.26% 
H^2 (total variability / sampling variability):  1.02 
 
Test for Heterogeneity:  
Q(df = 11) = 9.7194, p-val = 0.5558 
 
Model Results: 
 
estimate       se     zval     pval    ci.lb    ci.ub           
 -0.0413   0.0301  -1.3717   0.1701  -0.1003   0.0177           
 
 
r) Effects of covariates: left MOFC <- global SANS + CPZ + gender + age + site (if applicable) 
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Shown below are the estimate, the standard error, p value and the confidence intervals 
for the meta-analytical standardized regression beta of global SANS scores on left MOFC 
thickness, controlling for current chlorpromazine equivalents (based on Woods et al. 
(2003)). Results were based on estimates from 12 studies. 
 
Random-Effects Model (k = 12; tau^2 estimator: REML) 
 
tau^2 (estimated amount of total heterogeneity): 0.0120 (SE = 
0.0104) 
tau (square root of estimated tau^2 value):      0.1093 
I^2 (total heterogeneity / total variability):   52.08% 
H^2 (total variability / sampling variability):  2.09 
 
Test for Heterogeneity:  
Q(df = 11) = 22.4039, p-val = 0.0214 
 
Model Results: 
 
estimate       se     zval     pval    ci.lb    ci.ub           
 -0.0950   0.0462  -2.0564   0.0397  -0.1856  -0.0045        *  
  
 
s) Effects in DSM-IV schizophrenia subtypes or schizoaffective / -phreniform disorder only: 
left MOFC <- global SANS + CPZ + gender + age + site (if applicable) 
 
Schizophrenia inclusion criteria were site-specific. In detail, five sites included only patients with 
DSM-IV subtypes of schizophrenia. Eight sites also included schizoaffective and schizophreniform 
Walton et al.                                                                           Negative symptoms and cortical thinning 
 
70 
 
patients in their samples, while only a minority of sites (Nsites=4; 7% of our total sample) also 
included a few patients with other psychotic disorders, such as psychotic disorder NOS.  
Of those sites where individual diagnostic codes for patients were available to us (Nsites=11, 
including the four sites with patients with other psychotic disorders), 77% of patients were 
diagnosed with Schizophrenia subtypes and 12% with schizoaffective / -phreniform disorders.  
To ensure that our results were not influenced by including patients with other psychotic 
disorders, we repeated the analyses including only patients with DSM-IV schizophrenia subtypes 
or schizoaffective / -phreniform disorders. 
Shown below are the estimate, the standard error, p value and the confidence intervals for the 
meta-analytical standardized regression beta of global SANS scores on left MOFC thickness, 
including only patients with DSM-IV schizophrenia subtypes or schizoaffective / -phreniform 
disorders. Results were based on estimates from 16 studies. 
 
Random-Effects Model (k = 16; tau^2 estimator: REML) 
 
tau^2 (estimated amount of total heterogeneity): 0.0060 (SE = 0.0061) 
tau (square root of estimated tau^2 value):      0.0774 
I^2 (total heterogeneity / total variability):   36.24% 
H^2 (total variability / sampling variability):  1.57 
 
Test for Heterogeneity:  
Q(df = 15) = 22.6004, p-val = 0.0930 
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Model Results: 
 
estimate       se     zval     pval    ci.lb    ci.ub           
 -0.0780   0.0339  -2.2992   0.0215  -0.1445  -0.0115        *  
  
 
 
SM 2.2 Exploratory analyses on ten more frontal regions 
 Univariate models were used to analyse the effect of negative symptoms on ten other 
frontal regions (separately for the left and right hemisphere; see SM Table 3s), controlling for sex, 
age and site (if applicable). After Bonferroni correction for multiple testing (ten regions per 
hemisphere = 20 tests), two regions remained significant on the left hemisphere, while no effect was 
observed in any of the regions on the right side (SM Table 3s). 
 
 
left hemisphere right hemisphere 
 
region-of-interest βstd p βstd p Nsites 
caudalmiddlefrontal -0.0196 0.5052 -0.0474 0.1406 17 
lateralorbitofrontal -0.0756 0.0017 -0.0732 0.0114 17 
caudalanteriorcingulate -0.0164 0.5169 -0.0547 0.0921 13 
parsopercularis -0.0821 0.001 -0.0357 0.2544 15 
parsorbitalis -0.0512 0.0512 -0.0479 0.0897 13 
parstriangularis -0.0659 0.0101 -0.0422 0.086 15 
rostralanteriorcingulate 0.0137 0.6022 -0.0434 0.1884 13 
rostralmiddlefrontal -0.0509 0.0446 -0.0484 0.0613 17 
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superiorfrontal -0.0662 0.0223 -0.0640 0.0264 17 
frontalpole -0.0398 0.1149 0.0006 0.9821 13 
 
SM Table 3s. Exploratory analyses on ten more frontal regions. 
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